CD274 and cholangiocarcinoma: Three PD-L1 ICIs have been reported, atezolizumab, durvalumab, and avelumab, including at least six clinical trials evaluating their possible role in combination with other monoclonal antibodies or chemotherapy drugs in advanced, metastatic, persistent or recurrent CC.